None
Quote | Beyond Air Inc. (NYSE:XAIR)
Last: | $ |
---|---|
Change Percent: | 0.18% |
Open: | $5.55 |
Close: | $5.53 |
High: | $5.7002 |
Low: | $5.30 |
Volume: | 63,857 |
Last Trade Date Time: | 02/12/2020 04:42:58 pm |
News | Beyond Air Inc. (NYSE:XAIR)
Beyond Air(R) (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (“NO”) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumor...
2024-03-20 09:18:23 ET More on Beyond Air Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Beyond Air Historical earnings data for Beyond Air Financial information for Beyond Air Read the full article o...
Message Board Posts | Beyond Air Inc. (NYSE:XAIR)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $XAIR 29% v1,29M c7.83 f29,8M H8.0299 ML5.72 | znewcar1 | investorshangout | 10/18/2022 8:42:42 PM |
Beyond Air To Participate in Three Upcoming Investor Conferences | delerious1 | investorshub | 09/29/2022 6:57:59 PM |
GARDEN CITY, N.Y., Dec. 09, 2021 (GLOBE NEWSWIRE) | delerious1 | investorshub | 09/29/2022 6:55:48 PM |
How is nitric oxide stored in the human body? | delerious1 | investorshub | 09/29/2022 6:55:09 PM |
Beyond Air ($XAIR) Investor Presentation - Slideshow | delerious1 | investorshub | 09/29/2022 6:53:08 PM |
News, Short Squeeze, Breakout and More Instantly...
Beyond Air Inc. Company Name:
XAIR Stock Symbol:
NYSE Market:
Beyond Air(R) (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (“NO”) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumor...
GARDEN CITY, N.Y., March 20, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to impro...
Commercial demand for LungFit ® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand PMA supplement for the expansion of LungFit PH label to include cardiac surgery accepted for filing and under substantive review by the FDA U.S. pilot t...